The Claim
Transplantation of Clostridium species and supplementation with ursodeoxycholic acid (UDCA) reduce statin-induced glucose intolerance in animal models.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In animal models, introducing Clostridium bacteria and giving ursodeoxycholic acid lowers elevated blood sugar caused by statin drugs.
See the scientific wording
Transplantation of Clostridium species and supplementation with ursodeoxycholic acid (UDCA) ameliorate statin-induced glucose intolerance in animal models, suggesting a potential mechanistic role for the gut microbiome and bile acids.
Statin use reduces certain gut bacteria called Clostridium, which changes the types of bile acids in the body. These altered bile acids reduce the production of a hormone called GLP-1, which normally tells the pancreas to release insulin after eating. With less GLP-1, the pancreas releases less insulin, causing blood sugar to rise. Giving back Clostridium bacteria or a specific bile acid called UDCA restores GLP-1 levels and normal insulin release.
What the research says
1 studyIn mice and humans, giving a specific gut bacteria (Clostridium) or a bile acid medicine (UDCA) helped lower the blood sugar rise caused by statins, showing these treatments might protect against this side effect.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.